restructuring quarters, the to Similar focus to Ginkgo's strategic costs on the our on going to update use section Mark. I'm you last and reduce efforts Thanks, X to first efforts.
change models cover the services. traditional by for last biopharma summer. Next, for data think trend industry CROs. We're it's And where companies made expansion how data science there. market have our into and is science nice life towards a customers tools going. and tools big opening I'll This now we haven't a AI on well in life some We needing served more a been there's I Ginkgo seeing
I'll share data good last customers the more we've details where been X specific points Finally, months. offerings automation, getting service traction Ginkgo and and on Ginkgo over tools with in the
Okay.
All started. right. get Let's
reduction our reiterated $XXX additional QX reduced the down in considerably reflected QX offset we set call in takeout. reduction a million annualized So that's Today, $XXX when facility. headwind to restructuring accelerated see consolidation cost achieved targets, we've quarterly And when related XXXX we achieved $XX and QX compared by announced being ago, in can BiofabX last QX, million for we charges site our set $XXX having million. a cut burn you our run those than for increased rate XXXX. target through rent to an a spending XXXX and cash we November, to that have partially where with million year less a
thrilled and a is said, of the I'm or margin the don't I take at and is absolutely you having burn bank equivalents important that while cash dilutive -- progress over cash our how of see As avoid still $XXX want XXX no QX. cash fundraising million to as here me so in to on having to to cash when a on you having safety with debt end very
biotech, for do strong change the keep XXXX, where and we're way. peers, are while lot to incredibly of and to and still a we lot There's hard 'XX, I want it to in but like in work team the position undergoing here. really a we get us to position, a really Among pursuing that to our thank work our I AI advanced technology plan in today. do from of Ginkgo
and cost is like XXXX, also our goal We between inclusive that's comparing see sales. trend cash of reflected QX My XXXX. can QX this You progress total chart like and the really this of revenue of to said, keep in going. expenses, I
lot we taken are target we As $XX shown being our better we've Mark changes given with government improvement even do guidance million to that our there. our R&D in already expenses, 'XX, I'm than revenue have we'll around conservative mentioned, further there. uncertainty funding, of steps hopeful cash drop obviously, But annual the a and as
on move changes in even footing see now. an not we Honestly, business and We this we're is summer. at is getting last the working solid and as easier showed can on working based the what throughout that We XXXX, very made Ginkgo. we quickly, more
the the only we year. changes in that can improve following rate So should make
moving really equipment team's work on on proud of map, of operational access technologies, their in the the Altar, down I'm and you out while customer those been for and critical various acquisition maintain to moving that particular, overall, delivery quick really retain in has also ability ensure the we of spinning to see this people work their sites Lesaffre impressive. and team
move been sites. what over and that those quickly really we out working, again, years being couple and drawbacks in too to in consolidate many face mistakes around were of able was we has and impressive. the of So past Those of the made were biotech
growing if am or please are we you hesitate available love space you Cambridge to for I looking friendliest lab still been but biotech, Boston. of lot in I subleases, reach to here. space out We've we'd the landlord on don't into. biotech a making say, will get headway that have
that mention still our delivering very corporate are I teaming RANGER at work maintain in on contracts, consolidation, that want site that note the despite new Europe later well a we and program. programmatic one European as I'll our technical exciting entities today, including to and and
right. Okay. All
So topic. right. let's the All to next move on
expanding our original mentioned and So been into I tools outside business services. has Ginkgo sort solutions of of
So where that color XXXX. more little I want headed on for give in to a we're
So JPMorgan, solutions deal of you -- first see, the historic right? our activities, a as can a to bit here, head are really was of selling checks, So we at see R&D included of this took milestones biopharma, downstream you royalties. the of kind sort large of form deals would close. big value were a multiyear the long like they or programs, They in time large and negotiated they the to
in reports solutions the or the not have for selling like, that tools. but in to look addition, of the we change the high -- deals. R&D at is risk was sort of is this really someone by customization this made Head Head a sort reports of company. the on R&D. person technical And We to quite tools, taken that of customer those big and on lot you the that XXXX -- if I doing we're chart The a R&D, still to And could Head of of reports biotech end, started
to unique would hoping in an biopharma biotech Cambridge a a it be large a extreme of form developing drug license So small partner. this and it to
risk, So end high that's high the end customization. of the licensing of sort at of asset model technical is
billion, drug preclinical for for least pre-commercial. also are -- can out of proven right? see at that, get you You clinically get these that for multibillion-dollar value assets or a You bought lot deals
do These and are Pfizer Ginkgo. on Nordisk discovery you our curve deals manufacturing, highly business R&D. so you customized, a that drug down support and bit, or go to Merck Novo to We right? with at these solutions As and got
royalties and of the top and there, than then more large royalties and bunch billion milestones of a $X.X are that. shared We sort Mark more aggregate getting whole milestones of of numbers on
highly then met customized, that to see we value hurts in ever commercialize the the and more to we are last downstream. And in certainly, us again, However, them. really don't but we're sometimes on revenue risk. quarter, the some We customers taking technical on And dependent milestones technical on than the side. meet big
-- just to. And so about second. talk talk get I'll great. a It about while in that's takes a I'll to
go middle taking sort you the dotted and what into as to that point customizing in to a you're lose That risk But amounts you reach their technical customers' where get on not of you much, not represents revenues the where line scalable you're through business. the more easily products.
we're data going to business customers about assets CRO, order large so research our AI to model for which like that's training. is organization, talk to data often akin generating a most traditional points, And contract for
web I'm really, equipment as not here And that AI try much going folks to that seeing We're business. talk released of is an traction Ginkgo, but today, our has at models should the up selling and really been the automation other business where going we've lot on out. then finally, we're platform we're about a well.
and near-term R&D for wider the at So customer's swath the cycle project and fee the upside sales to term do faster driving, it's we customer. and where customer a again, of a show we got left-hand much Ginkgo get technology right-hand product, a to scientist we've we get side, piece of side, a larger potential but customer, longer rolled up every on get that on revenue, really
they are very tools, helping So are having business is very solutions Us these I the us different. but really sell think complementary.
And year. risk this jumping was into it a last so
the AI on heads priority around going assets and has also industry. And sort of companies, to products. R&D but AI interest for develop internally their off well the data the is to that it to customer or X happy drive large that And us. both so and seeing paid is you're new even that list, them enable of help go in talk really in we're of if biotech organization, to And models hear efficiency in I'm X CEOs pharma has reason the so that, see to you to
And butt partnership lot area there's it's have of as the industry, in a off the of and sort ago of Recursion kind this in interested applicability of from driving more a this, in the that And later tech I'll improved particular, has in think which But really in of and Genentech industry, more the this -- bit by of you the -- later few demonstrated talk I target kicked little this. a that. kick between discovery, data about a a points. models owes for only people saw getting AI the years
frame mean want So to tools industry. science the for like this life what does I
a the of science on is I a can It of at think right? life I ago the a market, flexible. is the sort traditional bench. as and So left-hand see tools couple you well, It's side, bring quarters this showed slide scientist maximally
literature scientist a a run a that and of they that about want they've an on perfect answer that results right? So want experiment, their experiment, to and lot in based to previous has question seen work, run to they have they hypothesis reading that
they run that perfect And want tomorrow. it experiment, to
these to equipment and them want and right to they to the all show a of reagents exactly it want. bunch very and assets experiment need be on short they they notice, have available on they be able up need to to site, So
want. So and can they SKUs these thousands providers the exactly of from huge tools thousands do big scientists what that with catalogs that, so
data tools And think need for the a because if model model training, see data you the drugs, about I our care get really from this important It's if all to what models biological data. By biotech more data different than lot infrastructure way, point these a better you is want you thing, lot just I AI we've and a AI per they generated, want you generate to training. for cost have infrastructure. developed learnings really think is this if generate right? the of come
that infinite you with don't scale case, you want sort in is what less of flexibility. flexibility, infinite so want And
experiments be In a lot want can the of data be you similarly so that the well. fact, done compared to
a And sort what stop approach we're think data this think very I doing complementary. I research Again, calling versus to foundry approach. I so going we're think of they're research classic don't discovery-based the companies, need to at have think I all biopharma institutes all major it but hypothesis-driven major science, the bio a really complement going you're we to out there. where research
You data large ability it sets to approach. this to approach models need of the in generate and with train order AI-based
going So to a products in lot half of positioned of that see I of well but think driver extremely made energy is second the you're tools this our for so underlying direction. We year. that's last we're think the Ginkgo, at well adoption go in this
Okay.
a which want I points most where is our automation traction, about specific, we've So the more now our and to product. X the products the talk seen data bit product
in So points our The we a go is solutions. very have data different if I'll model here. you to business first is point this than thing out
data for points is customers royalties. our large are when assets no intellectual really a data milestones. they There own basis generating There's fee-for-service seeing the those offering, customers. no property. So all on We're
products to developability. going genomics already and the There's that X be are antibody data points functional launched,
about talk genomics. I'll functional So
exciting. this First, is really
to take have may so by XX,XXX to do pretty hit perturb type with used models a a that X cell developed a against in or or really mentioned a in partnership in-house for is new chemicals to in AI to they to it they they targets want drugs perturb that what have models. and find to that that's relevant I academic Genentech-Recursion develop customer what want be their often the And disease compound either disease want in perturb example, spirit XX,XXX similar they they where is genetically. that's will maybe they or to out to that target And it cell discovery, a standard I library, this So to might chemical you're want with type. think mean literature library using
gene maybe And sell it of like to we out to maybe would high read popular most types has in complexity on in a want so out would cell. to do, they a you different be time genes measurements compound, can like words, X,XXX, transcriptomics. few well. have with cell. other knockouts a we CRISPR host performance XX,XXX hit far you X,XXX, that of the then you X And In And of knock but that been each that the measurement a make or
are And sort of give cells but imagery, both those can content give profile, also painting cell you back do readout ] thousands high Brightfield so we that these you able to transcriptomic on a [ we and of to the cell of with many high outputs.
the done We've that ones types cell different you the that but we've human on at already with XXX in now Ginkgo, there, this see been that drug-seq that left have worked can we've onboarded for high skin so really that. forth. cells, good transcriptomics cells, got normal And rate CAR on doing online. myoblasts, and cells customers, HeLa an have so issue hit don't doing We've been T fibroblasts, for we a really skeletal content bringing
at again, So that customer to we're have cells we cells with here happy Ginkgo. or work
have that people sets you data get just of that just is the think here at really with out ahead and that and put we gone that work of points. teams for I folks them some just can data Ginkgo developed format we've ML see and Also, AI liked online paid and so data
compounds data. attention of biggest the chemical There's nearly And to so draw GDPxX data launched XX data here. I'll terabyte set, we've set is X your our
and them X drug compounds. sort are or rest controls X of are think I of the
transcriptomic of data We and again, online. of gig a It's We then X about we cell do hit X per replicates that readout type X cells. all those plates, across concentrations different that, put in these cell types then and drugs with XXX-well of that. XXX different
And download it. so
download a new to play that people been good really exactly get. it. QR to that customers way shows around You they're that's bring code, in And going can and what hit with for product. It
product. data talk product I'll next antibody developability in our points The is about
you assays them. antibodies can XXX, synthesize, send developability sequences. Here battery then send are antibody us the us ideas a run those of you We'll on can and express X,XXX
And heparin see but thermostability like list so things here, and you can binding a and these polyspecificity. are
run things complex, to really are assays. difficult Some
And cloud, very in to get unique again that able back I so data get being these in to clean over of format offering a the the at market. thousands is think, throughput a a you AI/ML-ready and
excited to And out so uptake. really we're that there, we've seen and have good
give projects. a what are sort example These of to And of like. look you timing X and just sense programs
first cells The see there. that's a go right get in of you would cell And X that compounds that types XX-week different after an project where could be XX- to data is oncology lines, we target then the you would project, this ID back. X,XXX
one next here ID Alzheimer's in interested be would a perturbations. for The an genetic target over
So in data genes CRISPR to asset. knockouts cell that across X case a types, those and of that's X,XXX this X- XX-week doing on return
formats on see come side, can of types that the right-hand the the back illustration data You of different you. to
So again, mention, we recently services, really an be out only next excited upcoming about and I thing will AI released RNA also RNA data this. will The models.
up, again, interested RNA, of service. rights for the the to other this space types RNA that no encourage working be they're using by data folks offerings if as see and of that AI exactly or tools But in us royalties and a of you call, will IP discovery, will same drug is terms the So X design in fee assets. the it something that give these be types coming can are generate you we can
call for genomics in you're addition RNA, large if and us a data to looking also of sets the in sort antibodies. So functional give
Okay.
want to Screening RAC the I Laboratory (sic) and and Lab came Automation Automation. Automation for for and ], there our of was in, it to guess, move exciting [ And Diego So in I data next Screening to I SLAS, ton Carts, Society of technology. say January Automation conference. points, really that's Society we on end there's -- near of the our actually be I San what in Ginkgo a because on interest Reconfigurable was
to work was company acquired the and of has into had And previous we these simpler, generation were You assets. the of acquisition X been we they it ago. over X the Zymergen big an get really new now. to the I felt really of years SLAS this them available at this Zymergen one happy a launch And acquired we reasons a carts more in ago few has had through manufacture, started years, want might and lot a that to making is that remember, This last carts came say, this we're when easier generation or of unique automation X.X reception. years gone they since then
work. these so understand Just how you
a inside have laboratory equipment. of the piece We cart
And move along you then of piece a So this okay? there's vendor equipment basically which want, there's for all of then any coming right, robotic bench lab bench there's from the you allows a to So a lab a is including piece been arm, at right? right? track, all a called and lab lab the rail. MagneMotion And lab that's developed plate magnetics the rail, in the cart, that's
together, any X of of the can you X to what one you here then you to parts in can image then and do the arms together And stitch and this equipment. can those the move put of samples carts piece X on them can delivered see get is
electronics And back software. the a cloud that our then of in and that part. inside of all cart Okay, equipment There's goes hardware to lot connected. the the is of bottom importantly,
and software. the itself on delivery control can both we So controlled samples, the by equipment sample the the is the arm then to the our putting of equipment
of adding equipment and see customer new already these are they're systems are based all already sort users the we've these either we put other interest, RACs we're into that hardware pieces on We're In this the new can things of plugged you of off-the-shelf software. interest adding Ginkgo or in And words, time. the because rapidly integrations. to
So not you just if this is equipment list, we'll of and you're at in know, interested and let get automation on it a piece it. integrated want us
is a hitting infinite called be doing reduction processes case but XX% and -- hands-on Octant stopped shared XXX,XXX We manual recently wisdom, is the did a that that a that of acquired actually pharma very Xx time. -- automation week. they've is now. we in running, selling start-up XXX-person they're selling good lab the meantime, like -- I this to was them a XX-person, in month, study. actually small samples from and to numbers company. like a mean the This and this in once national teams my they XXX,XXX samples I And started to -- X automation automation they a a Octant. both increase to prior engineer couple an so acquiring is have Happy and operators had it's their throughput from Ginkgo And about company. hardware a Zymergen, sell sold And it and this over
sort traditionally really in has able pretty it's And automation a different work able scale data of do case, reaction. or would team really dedicated very scale this number a generate And team let specific that's cell of things. do of generation lean require to a to to and large of be Octant automation that been designed X that
in Ginkgo automation. automation vendors, can own uses You also here see unique our our among Boston, setup equipment
So business, do because of we of facility a because Solutions in R&D lot biotech Boston. in our our data points, here and of
So last these of carts see since we in actually bringing over the Ginkgo to couple that been Boston generation of the Zymergen years automation can the you the older have acquisition. are these
originally And this by in different about the the block But rails. first are just equipment, then LEGO add thing were this the able what's was we is aimed prep. of DNA and automation. neat schematic it was PCR And of That same all system the running our Boston. do style, prep, RAC we here in adding is more pieces library all of that what on assembly pieces NGS equipment onto of those the set up to to now really
really And a something custom excited sell about one-off project. are the people this that because you engineering vendors is integrated automation at traditional SLAS basically
whatever, I a week. want want You're run. I want up high a set This look to run screening compound. $XXX,XXX like a for, drug assay the to to throughput is I
Okay, great.
You need everything this really up rolls do equipment. is There's set a whole XD file. then There's that X later. a X custom it and out months software to built and build
later, thing to want a a are if then build And years the there, say you and running scrapping protocol mind new one. you basically your on different change X
several And the able X big been workflows RACs, expand system Boston. system in now times so to we've here with whereas onto add to new the
that is so prop at unique SLAS. excited a And selling that folks really were about
can like selling booth SLAS. late equipment I'll up SLAS. at to directly, you start we see thing to because we One As mention midyear is our decided were signing the like is at
at Our next it the to back, the entire bathrooms and like was time. the mobbed booth was
think this of are itself. So I idea into do built people about hardware really modularity excited the
Okay.
to right, were how add them JPMorgan an have together. you like at something the in where they to isn't sense engineering get to a a took effort and they today are to just else, for carts our improvement them top of we give a or invite the rapid nice up this there. of rapidly And there's software automation ton Recursion physical enough had us can to these at place party So us
just system on up cocktail plates the party, we equipment had put a few there's a RAC afternoon so And hours. up, moving that and running, to getting the those picked all in around, carts set actually
by of enabled so type really a automation. And of the build-out is modular that speed
set don't describe it's automation that adjust to really rather system importantly, know impactful I'd change to and and The an as an automation in core that it's and I you nice up to it. automation you hours, people is it X like work think but expand cell. to than nice and idea an can know need can economically
that instead throughput do university. It's company doing your to expand to or of an need or need you're you in grow high AI thing. going as a at you new one automation So site protocols whatever and really a
systems. selling of Speaking
So announced Center. of January while. sold at Really excited we Great end Bioenergy a to a about systems this. the Lakes see back in to excited we out the Super that Research system just going
We of these have but interested a great in importantly, people pipeline, SLAS, a now. ton evaluating after both before systems
out us. reach please to So
of If an you're either cell to this idea currently interest automation is or build interested core you. automation work to in of planning
the I'm today, all it of not software going is RAC into operates cloud-based. to that get but the
in really we which scheduler, constraint-based a think is the leading have We industry.
the have also system. early have a lot with That's customers debugging, itself a systems, and and -- can arms, that. of of the the at-a-distance We we on not just equipment really liked form the neat we tracks do cameras the basically monitor all of but and
stuff on integrated standardizes automation a here sort is, of this that last platform that thing industry. look, this could the And is I'll say big the dream the become across horizontal lab
data they why so immediately excited of folks you done not the of one want about there's and to generate by this to have things this? data, tech we more automate the is these don't look they're is well, to they we that, that expensive robots? generated. to run don't number and data, AI lot really are of sort issue use how into be seeing biotechnology So Why all applying and very I'm one, able It's and a and AI, idea they go at hand, that jumped science
the doing there's And in of the work challenge just science. much variability is big so
is up make Yes, industry, at start connect. to so us we sort allow be to is it. easy. ahead needs easy to to And equipment, I excited it frankly, hardware RACs the all It an connect need be be to to with really And think of software think software to level. about they're modularize do. the but easy level, come what and as that at the I And going that standards
European HaDEA, European Digital Health the key some of in but the we Health the at to through of to very by going exciting Preparedness thing Response linked we're funded about Biosecurity last today time HERA, The I about started Biosecurity a talk the to ton work general, Emergency the Authority, getting EUXHealth Commission. Okay. program Executive Agency, and and want have are priorities is talk on to
bit We'll million XX be worth I've up of of a to for leading ] been what [ nerd tried disease. Star Trek up project an EUR -- as international like partner to of a make sort consortium a for thinking
sick, I'm say, is "Hey, available to I to and what look NGS point sequencing have?" And have virus metagenomic so care do and of sort the of idea here
There's to many that to result. be too sample just And that today, you're the genome. actually steps really getting and at And between would the not best that's way available. do the look
care. it's not so And point really of
to is we those here so of start And could out build some idea the technologies.
should needs that think the ultimately direction know right? right? I there's feel would almost if off just as Biosecurity neat, Ebola Like detector, know would to there this to this I as alarm, So and if to Biosecurity set should is that eventually, smoke go is this Like a right like in, was I now, room much really like an like in smoke.
is and really able that over And a in on. DNA so I kicking breakthroughs think viruses and that monitor Europe. be time being lot of technically circulating excited requires it so and a I'm off feasible, to lot it's engineering to And of work, project and but
Okay.
offerings, deliver proud our for to delivering extremely our to this I'm customers we on cut targets. excited as back across and of we have the continuously EBITDA opportunity towards strive conclusion, for by all in I'm still continue we as continue adjusted while our breakeven So ahead us quarter our We execution of mid-XXXX. revenue costs,
All right.
to going Joseph Q&A. to back for it hand I'm Now
